Log in

Relevant bibliographies by topics / Fosphenytoin / Journal articles

To see the other types of publications on this topic, follow the link: Fosphenytoin.

Journal articles on the topic 'Fosphenytoin'

Author: Grafiati

Published: 7 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Fosphenytoin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

&NA;. "Fosphenytoin." Reactions Weekly &NA;, no. 1379 (2011): 19. http://dx.doi.org/10.2165/00128415-201113790-00069.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Fischer, James H., Tejal V. Patel, and Patricia A. Fischer. "Fosphenytoin." Clinical Pharmacokinetics 42, no. 1 (2003): 33–58. http://dx.doi.org/10.2165/00003088-200342010-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Fosphenytoin." Reactions Weekly &NA;, no. 1076 (2005): 9. http://dx.doi.org/10.2165/00128415-200510760-00028.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Fosphenytoin." Reactions Weekly &NA;, no. 913 (2002): 7. http://dx.doi.org/10.2165/00128415-200209130-00020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Holliday, Stephen M., Paul Benfield, and Greg L. Plosker. "Fosphenytoin." PharmacoEconomics 14, no. 6 (1998): 685–90. http://dx.doi.org/10.2165/00019053-199814060-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Fosphenytoin." Drugs & Therapy Perspectives 4, no. 9 (1994): 7–8. http://dx.doi.org/10.2165/00042310-199404090-00003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Fosphenytoin." Reactions Weekly &NA;, no. 949 (2003): 11. http://dx.doi.org/10.2165/00128415-200309490-00041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Fosphenytoin." Dimensions of Critical Care Nursing 20, no. 3 (2001): 12. http://dx.doi.org/10.1097/00003465-200105000-00004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Luer, Mark. "Fosphenytoin." Neurological Research 20, no. 2 (1998): 178–82. http://dx.doi.org/10.1080/01616412.1998.11740502.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Cheshire, William P. "Fosphenytoin." Journal of Pain and Symptom Management 21, no. 6 (2001): 506–10. http://dx.doi.org/10.1016/s0885-3924(01)00269-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Eriksson, Kai, Tapani Keränen, and Reetta Kälviäinen. "Fosphenytoin." Expert Opinion on Drug Metabolism & Toxicology 5, no. 6 (2009): 695–701. http://dx.doi.org/10.1517/17425250902997975.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Knapp, Lloyd E., and Alan R. Kugler. "Clinical Experience With Fosphenytoin in Adults: Pharmacokinetics, Safety, and Efficacy." Journal of Child Neurology 13, no. 1_suppl (1998): S15—S18. http://dx.doi.org/10.1177/0883073898013001051.

Full text

Abstract:

Fosphenytoin, a prodrug of phenytoin, is rapidly and completely converted to phenytoin in adults after intravenous or intramuscular administration and is significantly better tolerated than parenteral phenytoin. Fosphenytoin is highly plasma-protein bound and, when present in sufficient concentration, will displace phenytoin from plasma proteins. The clinical utility is that fosphenytoin may be used to achieve therapeutic phenytoin concentrations more rapidly than intravenous phenytoin infused at its maximum recommended rate. In a clinical study of generalized convulsive status epilepticus, fo

APA, Harvard, Vancouver, ISO, and other styles

13

Kugler, Alan R., Thomas M. Annesley, Gerald D. Nordblom, Jeffrey R. Koup, and Stephen C. Olson. "Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays." Clinical Chemistry 44, no. 7 (1998): 1474–80. http://dx.doi.org/10.1093/clinchem/44.7.1474.

Full text

Abstract:

Abstract The cross-reactivity of fosphenytoin, a phosphate ester prodrug of phenytoin, was investigated in the Abbott phenytoin TDx®/TDxFLxTM fluorescence polarization immunoassay (TDx) and the Behring Diagnostics phenytoin Emit® 2000 enzyme-multiplied immunoassay (Emit). The first part of our study investigating cross-reactivity utilized in vitro correlation of the two immunoassays with a validated and specific phenytoin HPLC method used to assay plasma samples prepared in several phenytoin and fosphenytoin concentration combinations. Fosphenytoin cross-reacted with both immunoassays, but to

APA, Harvard, Vancouver, ISO, and other styles

14

Fischer, James H., Michael J. Cwik, Mark S. Luer, Carolyn B. Sibley, and Kelly L. Deyo. "Stability of Fosphenytoin Sodium with Intravenous Solutions in Glass Bottles, Polyvinyl Chloride Bags, and Polypropylene Syringes." Annals of Pharmacotherapy 31, no. 5 (1997): 553–59. http://dx.doi.org/10.1177/106002809703100505.

Full text

Abstract:

OBJECTIVE: To determine the stability of fosphenytoin sodium admixtures with NaCl 0.9% injection and dextrose 5% (D5W) injection when stored in glass or polyvinyl chloride (PVC) containers, to evaluate the compatibility of fosphenytoin with 11 other intravenous solutions, and to determine the stability of fosphenytoin repackaged in polypropylene syringes. METHODS: Dilutions of fosphenytoin sodium 1, 8, and 20 mg phenytoin sodium equivalents (PE)/mL were prepared in NaCl 0.9%, D5W, and 11 other intravenous fluids. Aliquots of each solution in NaCL 0.9% or D5W were transferred to three glass bot

APA, Harvard, Vancouver, ISO, and other styles

15

Boucher, Bradley A., Claudio A. Feler, J. Christine Dean, et al. "The Safety, Tolerability, and Pharmacokinetics of Fosphenytoin after Intramuscular and Intravenous Administration in Neurosurgery Patients." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 16, no. 4 (1996): 638–45. http://dx.doi.org/10.1002/j.1875-9114.1996.tb03646.x.

Full text

Abstract:

Study Objective. To evaluate the safety, tolerability, and pharmacokinetic profile of fosphenytoin, a water‐soluble phenytoin prodrug, after intramuscular and intravenous administration.Design. Open‐label study of intramuscular administration, and double‐blind, randomized study of intravenous administration.Setting. Six and ten hospitals throughout the United States for the intramuscular and intravenous multicenter studies, respectively.Patients. Neurosurgical patients who required anticonvulsant prophylaxis or treatment.Interventions. In the intramuscular study, 118 patients received loading

APA, Harvard, Vancouver, ISO, and other styles

16

Boucher, Bradley A. "Fosphenytoin: A Novel Phenytoin Prodrug." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 16, no. 5 (1996): 777–91. http://dx.doi.org/10.1002/j.1875-9114.1996.tb02996.x.

Full text

Abstract:

Fosphenytoin is a phenytoin prodrug that received an approvable letter from the Food and Drug Administration in February 1996. It was designed to overcome many of the shortcomings associated with parenteral phenytoin sodium. Specifically, fosphenytoin is a highly water‐soluble, phosphate ester of phenytoin that has no known pharmacologic activity before its conversion to phenytoin. Dosing of fosphenytoin uses phenytoin equivalents (PE) to minimize dosage errors when converting from the conventional formulation. Pharmacokinetic studies documented that the agent is rapidly and completely convert

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Fosphenytoin/phenytoin." Reactions Weekly &NA;, no. 1223 (2008): 14–15. http://dx.doi.org/10.2165/00128415-200812230-00043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

&NA;. "FOSPHENYTOIN (CEREBYX)." American Journal of Nursing 97, no. 1 (1997): 62. http://dx.doi.org/10.1097/00000446-199701000-00042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Chioffi, Susan M., Timothy F. Lassiter, Ann C. Scates, and Beth M. McLendon. "FOSPHENYTOIN FACTS." American Journal of Nursing 99, no. 8 (1999): 14. http://dx.doi.org/10.1097/00000446-199908000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Browne, Thomas R. "Fosphenytoin (Cerebyx)." Clinical Neuropharmacology 20, no. 1 (1997): 1–12. http://dx.doi.org/10.1097/00002826-199702000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Ramsay, R. Eugene, and B. J. Wilder. "PARENTERAL FOSPHENYTOIN." Neurologist 5, no. 4 (1998): S35. http://dx.doi.org/10.1097/00127893-199809010-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Chioffi, Susan M., Timothy F. Lassiter, Ann C. Scates, and Beth M. McLendon. "Fosphenytoin Facts." American Journal of Nursing 99, no. 8 (1999): 14. http://dx.doi.org/10.2307/3472163.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Horowitz, B. Zane. "Fosphenytoin farewell?" Annals of Emergency Medicine 43, no. 3 (2004): 398–400. http://dx.doi.org/10.1016/j.annemergmed.2003.11.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Mueller, Eric W., and Bradley A. Boucher. "Fosphenytoin: Current Place in Therapy." Journal of Pediatric Pharmacology and Therapeutics 9, no. 4 (2004): 265–73. http://dx.doi.org/10.5863/1551-6776-9.4.265.

Full text

Abstract:

Fosphenytoin is a parenteral phosphate ester prodrug of phenytoin developed to overcome the limitations associated with parenteral administration of phenytoin. Despite potential clinical advantages, pharmacoeconomic concerns have prevented widespread substitution of parenteral phenytoin with fosphenytoin. The purposes of this descriptive review are to (1) highlight recent clinical and pharmacoeconomic data regarding the therapeutic decision to use phenytoin or fosphenytoin for the parenteral management of acute seizures, and (2) discuss the implications of fosphenytoin use in neonatal and pedi

APA, Harvard, Vancouver, ISO, and other styles

25

Roberts, William L., Barun K. De, John P. Coleman, and Thomas M. Annesley. "Falsely Increased Immunoassay Measurements of Total and Unbound Phenytoin in Critically Ill Uremic Patients Receiving Fosphenytoin." Clinical Chemistry 45, no. 6 (1999): 829–37. http://dx.doi.org/10.1093/clinchem/45.6.829.

Full text

Abstract:

Abstract Background: Fosphenytoin, a phosphate ester prodrug of phenytoin, is metabolized to phenytoin in vivo. Phenytoin metabolites accumulate in renal insufficiency and cross-react in some phenytoin immunoassays. Our aim was to determine the accuracy of phenytoin immunoassays in renal patients treated with fosphenytoin. Methods: We measured phenytoin with HPLC and with the aca, ACS:180, TDx phenytoin II, Vitros, and AxSYM methods. Specimens were collected 2–120 h after fosphenytoin administration from 17 patients with renal insufficiency. Results: The AxSYM, TDx phenytoin II, ACS:180, and V

APA, Harvard, Vancouver, ISO, and other styles

26

Clark, Sarah L., Megan R. Leloux, Ross A. Dierkhising, Gregory D. Cascino, and Sara E. Hocker. "IV fosphenytoin in obese patients." Neurology: Clinical Practice 7, no. 1 (2016): 45–52. http://dx.doi.org/10.1212/cpj.0000000000000322.

Full text

Abstract:

AbstractBackground:Previous studies evaluated the disposition of IV phenytoin loading doses and found that obese patients had increased drug distribution into excess body weight, larger volumes of distribution, and longer half-lives when compared to their nonobese counterparts. We assess the safety and efficacy of fosphenytoin loading doses in patients with different body mass indices (BMIs).Methods:A retrospective chart review was conducted in 410 patients who received fosphenytoin. Patients were divided into 2 groups: BMI <30 (nonobese) and BMI ≥30 (obese). Patient demographics, fosphenyt

APA, Harvard, Vancouver, ISO, and other styles

27

Prusakov, Ashley B., Anup D. Patel, and Justin W. Cole. "Impact of Obesity on Fosphenytoin Volume of Distribution in Pediatric Patients." Journal of Child Neurology 33, no. 8 (2018): 534–36. http://dx.doi.org/10.1177/0883073818770801.

Full text

Abstract:

The impact of body habitus on fosphenytoin pharmacokinetics is poorly understood in pediatric patients. This retrospective, single-center review examined differences in fosphenytoin volume of distribution (VD) between children with normal and obese body habitus. From 2013 to 2015, patients 2 to 18 years of age who received a loading dose of fosphenytoin were identified. Thirty-seven patients met inclusion criteria. Mean total serum phenytoin concentration was 25.3 ± 6.5 μg/mL in the nonobese group and 29.5 ± 7.6 μg/mL in the obese group ( P = .09). VD was not significantly different between ob

APA, Harvard, Vancouver, ISO, and other styles

28

Alix, Veronica, Mansi James, Anthony H. Jackson, Paul F. Visintainer, and Rachana Singh. "Efficacy of Fosphenytoin as First-Line Antiseizure Medication for Neonatal Seizures Compared to Phenobarbital." Journal of Child Neurology 36, no. 1 (2020): 30–37. http://dx.doi.org/10.1177/0883073820947514.

Full text

Abstract:

Currently used treatment protocols for neonatal seizures vary among centers with limited evidence to support the choice of a given antiseizure medication. Because of concerns about the potential negative impact of phenobarbital on long-term neurodevelopment outcomes, our unit transitioned to fosphenytoin as the first-line antiseizure medication. A retrospective observational cohort study was conducted to compare the acute and long-term outcomes of fosphenytoin and phenobarbital as first-line antiseizure medication for neonatal seizure treatment. The 2 study groups had similar baseline characte

APA, Harvard, Vancouver, ISO, and other styles

29

Graves, Nina. "Pharmacoeconomic Considerations in Treatment Options for Acute Seizures." Journal of Child Neurology 13, no. 1_suppl (1998): S27—S29. http://dx.doi.org/10.1177/0883073898013001081.

Full text

Abstract:

Two pharmacoeconomic studies on the treatment of acute seizures have been conducted. In 1991, Kriel and colleagues surveyed parents of children with a history of cluster seizures, prolonged seizures, or status epilepticus who had been instructed in the use of rectal diazepam. A comparison of data before instruction with data after instruction showed a reduced need for emergency department visits with rectal diazepam. Instruction thus provided a pharmacoeconomic benefit, despite the cost of the product. In 1996, Marchetti and coworkers found that intravenous fosphenytoin was associated with few

APA, Harvard, Vancouver, ISO, and other styles

30

&NA;. "Fosphenytoin/phenytoin overdose." Reactions Weekly &NA;, no. 1391 (2012): 23. http://dx.doi.org/10.2165/00128415-201213910-00085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Kirschbaum, Karen, and Cheryle Gurk-Turner. "Phenytoin vs Fosphenytoin." Baylor University Medical Center Proceedings 12, no. 3 (1999): 168–72. http://dx.doi.org/10.1080/08998280.1999.11930167.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Takeoka, Masanori, Kalpathy S. Krishnamoorthy, Teesta B. Soman, and Verne S. Caviness. "Fosphenytoin in Infants." Journal of Child Neurology 13, no. 11 (1998): 537–40. http://dx.doi.org/10.1177/088307389801301102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Annesley, Thomas M., Stephen Kurzyniec, Gerald D. Nordblom, et al. "Glucuronidation of Prodrug Reactive Site: Isolation and Characterization of Oxymethylglucuronide Metabolite of Fosphenytoin." Clinical Chemistry 47, no. 5 (2001): 910–18. http://dx.doi.org/10.1093/clinchem/47.5.910.

Full text

Abstract:

Abstract Background: This investigation was undertaken to identify the structure of a novel immunoreactive metabolite derived from fosphenytoin that has been hypothesized previously as present in sera from renally impaired patients receiving this prodrug. Methods: The metabolite was isolated from uremic sera using solid-phase extraction and HPLC. Structural analysis was performed using HPLC–tandem mass spectrometry, nuclear magnetic resonance (NMR), deuterium exchange, and chemical derivatization. Immunoreactivity was evaluated using a fluorescence polarization immunoassay. Results: The metabo

APA, Harvard, Vancouver, ISO, and other styles

34

Bohannon, Kristin K., Noelle Leung, Aaron M. Cook, et al. "Evaluation of Two Fosphenytoin Loading Dose Regimens and Monitoring in Infants and Neonates Less Than Six Months of Age." Journal of Pediatric Pharmacology and Therapeutics 25, no. 7 (2020): 617–22. http://dx.doi.org/10.5863/1551-6776-25.7.617.

Full text

Abstract:

OBJECTIVES The objectives of the study were to compare the free serum concentrations after different fosphenytoin loading dose strategies in patients younger than 6 months old and to investigate the frequency of seizure cessation following a loading dose of fosphenytoin. METHODS This retrospective cohort study included neonates and infants admitted to a 150-bed children's hospital between August 1, 2014, and February 1, 2018. Patients were included if they were younger than 6 months old and had a postload free phenytoin serum concentration collected during the specified time frame. Patients we

APA, Harvard, Vancouver, ISO, and other styles

35

Gadd, Nancy J. "Probable Anticonvulsant Hypersensitivity Syndrome Due to Fosphenytoin in a Pediatric Patient with Streptococcus pneumoniae Meningitis." Journal of Pediatric Pharmacology and Therapeutics 12, no. 4 (2007): 224–28. http://dx.doi.org/10.5863/1551-6776-12.4.224.

Full text

Abstract:

An 8-year-old previously healthy girl with Streptococcus pneumoniae meningitis developed probable anticonvulsant hypersensitivity syndrome (AHS) within 5 days of starting fosphenytoin. She experienced fever, rash, periorbital edema, profound hepatotoxicity and coagulopathy. Her sudden and dramatic rise in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) to greater than 80 times the upper limit of normal in combination with an elevated INR were very concerning. Mortality from AHS has been correlated with the degree of hepatic involvement. Fosphenytoin was immediately disconti

APA, Harvard, Vancouver, ISO, and other styles

36

&NA;. "Esomeprazole/fosphenytoin/phenytoin interaction." Reactions Weekly &NA;, no. 1313 (2010): 19–20. http://dx.doi.org/10.2165/00128415-201013130-00065.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Wainwright, Mark S. "Fat, Pharmacokinetics, and Fosphenytoin." Pediatric Critical Care Medicine 19, no. 8 (2018): 784–85. http://dx.doi.org/10.1097/pcc.0000000000001647.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Hutt, Nancy. "FOSPHENYTOIN for Seizure Control." American Journal of Nursing 99, no. 3 (1999): 52. http://dx.doi.org/10.1097/00000446-199903000-00037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Anderson, Becky L. "New Anticonvulsant Agent: Fosphenytoin." Baylor University Medical Center Proceedings 9, no. 3 (1996): 41–42. http://dx.doi.org/10.1080/08998280.1996.11929985.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Pellock, J. M. "Fosphenytoin use in children." Neurology 46, Issue 6, Supplement 1 (1996): 14S—16S. http://dx.doi.org/10.1212/wnl.46.6_suppl_1.14s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Eldon, Michael A., Lloyd E. Knapp, and Alan R. Kugler. "CLINICAL PHARMACOKINETICS OF FOSPHENYTOIN." Neurologist 5, no. 4 (1998): S30. http://dx.doi.org/10.1097/00127893-199809010-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Paloucek, Frank P. "Fosphenytoin safety and economics." American Journal of Health-System Pharmacy 53, no. 22 (1996): 2702–6. http://dx.doi.org/10.1093/ajhp/53.22.2702.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Fierro, Lesley S., Donna H. Savulich, and Diane A. Benezra. "Safety of fosphenytoin sodium." American Journal of Health-System Pharmacy 53, no. 22 (1996): 2707–12. http://dx.doi.org/10.1093/ajhp/53.22.2707.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Morton, Lawrence Daniel. "Clinical Experience With Fosphenytoin in Children." Journal of Child Neurology 13, no. 1_suppl (1998): S19—S22. http://dx.doi.org/10.1177/0883073898013001061.

Full text

Abstract:

Fosphenytoin, a phenytoin prodrug, can be administered in a variety of intravenous diluents and has a more neutral pH value than phenytoin. The pharmacokinetics, safety, and tolerability of fosphenytoin in children from 1 day to 16 years old have been evaluated in two multicenter studies. Data are available from 78 patients who received loading doses (62 with intravenous administration and 16 with intramuscular administration). In these studies, fosphenytoin was converted to phenytoin within 8.3 minutes (range, 2.5-18.5 minutes). In addition, no significant difference in conversion rates was n

APA, Harvard, Vancouver, ISO, and other styles

45

Pon, PharmD, Doreen, Joon Hwang, PharmD Candidate, Teresa Lo, PharmD Candidate, and Carin Van Zyl, MD, FACEP. "Decreased responsiveness to oxycodone: A case of a pharmacokinetic drug interaction?" Journal of Opioid Management 11, no. 4 (2015): 357. http://dx.doi.org/10.5055/jom.2015.0284.

Full text

Abstract:

Concurrent administration of oxycodone and phenytoin may cause, through induction of CYP3A4 enzymes, decreased analgesic effects of oxycodone. However, no descriptions of this interaction exist. A patient who was on oxycodone for chronic back pain was admitted to the hospital. Five days after initiating fosphenytoin, the patient experienced a dramatic escalation in his pain and lack of response to oxycodone breakthrough doses. Changing oxycodone to hydromorphone resulted in significantly improved analgesia. Concurrent use of fosphenytoin and oxycodone may increase the conversion of oxycodone t

APA, Harvard, Vancouver, ISO, and other styles

46

Applebaum, Julia, Joseph Levine, and R. H. Belmaker. "Intravenous Fosphenytoin in Acute Mania." Journal of Clinical Psychiatry 64, no. 4 (2003): 408–9. http://dx.doi.org/10.4088/jcp.v64n0408.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Millichap, J. Gordon. "Fosphenytoin in Infants and Children." Pediatric Neurology Briefs 12, no. 11 (1998): 87. http://dx.doi.org/10.15844/pedneurbriefs-12-11-11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Browne, T. R., A. R. Kugler, and M. A. Eldon. "Pharmacology and pharmacokinetics of fosphenytoin." Neurology 46, Issue 6, Supplement 1 (1996): 3S—7S. http://dx.doi.org/10.1212/wnl.46.6_suppl_1.3s.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Pruitt, Alicia C. "More on fosphenytoin (Cerebyx) dosing." Journal of Emergency Nursing 24, no. 1 (1998): 6. http://dx.doi.org/10.1016/s0099-1767(98)90154-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Stella, Valentino J. "A case for prodrugs: Fosphenytoin." Advanced Drug Delivery Reviews 19, no. 2 (1996): 311–30. http://dx.doi.org/10.1016/0169-409x(95)00112-k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!